Efficacy and safety of Herceptin in women with Her2-positive (HER2+) metastatic breast cancer (MBC) who have progressed on a prior herceptin-containing regimen.

被引：0

作者：

Gelmon, K ^{[1
]}

Mackey, J ^{[1
]}

Verma, S ^{[1
]}

Gertler, SZ ^{[1
]}

Bangermann, N ^{[1
]}

Klimo, P ^{[1
]}

Schneeweiss, A ^{[1
]}

Bremer, K ^{[1
]}

Soulieres, D ^{[1
]}

Tonkin, K ^{[1
]}

Bell, R ^{[1
]}

Heinrich, B ^{[1
]}

机构：

[1] BC Canc Agcy, Vancouver, BC, Canada

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

440

引用

页码：S113 / S113

页数：1

共 50 条

[21] Pneumocystis jirovecii Pneumonia in a Patient with HER2-Positive Breast Cancer Treated with Trastuzumab (Herceptin)
Van der Putten, S.
Blazkova, S.
IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : S240 - S241
[22] Kinetic Modeling of DUSP Regulation in Herceptin-Resistant HER2-Positive Breast Cancer
Buiga, Petronela
Elson, Ari
Tabernero, Lydia
Schwartz, Jean-Marc
GENES, 2019, 10 (08)
[23] Herceptin®-conjugated nanocarriers for targeted imaging and treatment of HER2-positive cancer
Mi, Yu
Liu, Yutao
Guo, Yajun
Feng, Si-Shen
NANOMEDICINE, 2011, 6 (02) : 311 - 312
[24] Herceptin - For metastatic breast cancer tumors that overexpress the HER2 protein
不详
FORMULARY, 1998, 33 (11) : 1046 - 1047
[25] Chemotherapy and herceptin for HER-2+ metastatic breast cancer:: The best drug?
Livingston, RB
Esteva, FJ
ONCOLOGIST, 2001, 6 (04): : 315 - 316
[26] Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).
Bartsch, R.
Berghoff, A.
Pluschnig, U.
Bago-Horvath, Z.
Dubsky, P. C.
Rottenfusser, A.
Wenzel, C.
Rudas, M.
Fitzal, F.
Dieckmann, K.
Gnant, M.
Zielinski, C.
Steger, G. G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[27] TRASTUZUMAB-BASED THERAPY AFTER DISEASE PROGRESSION FOLLOWING LAPATINIB AND CAPECITABINE IN HER2-POSITIVE (HER2+) METASTATIC BREAST CANCER (MBC)
Metro, G.
Fabi, A.
Foglietta, J.
Russillo, M.
Stocchi, L.
Crino, L.
Papaldo, P.
Sperduti, I.
Cognetti, F.
Gori, S.
ANNALS OF ONCOLOGY, 2010, 21 : 100 - 101
[28] Evidence, Experience, Efficiency: Herceptin® in the adjuvant Treatment of HER2-positive Breast Cancer for 10 Years
不详
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (06) : 408 - 408
[29] Evidence, Experience, Effectiveness 10 Years Herceptin in the adjuvant Treatment of the HER2-positive Breast Cancer
不详
BREAST CARE, 2016, 11 (03) : 228 - 228
[30] Safety of Herceptin monotherapy administered on a 3-weekly schedule:: preliminary data from a phase II study in women with HER2-positive metastatic breast cancer
Baselga, J
Castañeda-Soto, NJ
Clemens, M
Green, M
Harvey, V
Barton, C
Morales, S
EUROPEAN JOURNAL OF CANCER, 2002, 38 : S95 - S95

← 1 2 3 4 5 →